For more information or confidential assistance
800-306-3180
se habla español

Diabetic Ketoacidosis Prompts Invokana Lawsuit

drugreporter.com
A California woman has filed a product lability lawsuit against Janssen Pharmaceuticals and Johnson & Johnson, alleging that the defendants’ product, Invokana, caused serious complications. Jennifer Anzo filed the Invokana lawsuit late in October 2015 in the U.S. District Court for the Eastern District of California. She is demanding compensation... Read more »

Plaintiff Blames Invokana for Severe Kidney Damage

Plaintiff Gene Schurman, a resident of Illinois, claims he suffered severe kidney damage after taking the diabetes drug Invokana under the direction of his doctor. He is now suing Janssen Pharmaceuticals, Johnson & Johnson and Mitsubishi Tanabe Pharma Corporation on claims of failure to warn, product liability, design defect, fraud,... Read more »

FDA Declines Approval of New Combination Diabetes Drug

London-based AstraZeneca failed to obtain FDA approval for a proposed diabetes drug that combines two different medications, saxagliptin and dapagliflozin. In October 2015, the FDA issued a complete response letter to the pharmaceutical giant’s application. The agency requested additional clinical research on the proposed combination drug. AstraZeneca recently released statements... Read more »

Invokana Targeted in Canadian Class Action Lawsuit

Already the subject of increasing controversy in the United States, next generation diabetes drug Invokana is now the target of a newly-filed class action lawsuit in Canada. Filed at the Ontario Superior Court of Justice, the lawsuit alleges that Jannsen’s treatment for Type 2 diabetes poses a serious risk of kidney... Read more »

FDA Updates Invokana Label Regarding Bone Fracture Risk

drugreporter.com
The U.S. Food and Drug Administration (FDA) has released a new drug safety communication regarding Invokana and Invokamet (canagliflozin). The safety announcement, which was released on September 10, 2015, adds a new warning to the drug’s label and updates the adverse reactions section with regard to the risk of bone... Read more »

Report Highlights Diabetic Ketoacidosis Risk Factors for SGLT2 Inhibitor Patients

Earlier this year, the U.S. Food and Drug Administration (FDA) published a safety communication that alerts consumers about an increased risk of diabetic ketoacidosis (DKA) with the use of sodium–glucose cotransporter 2 (SGLT2) inhibitors, including Invokana, Invokamet, Farxiga, Jardiance and others. Diabetic ketoacidosis is a potentially life-threatening complication of diabetes... Read more »